US Patent

US10537520 — Stable liquid formulations of melphalan

Formulation · Assigned to Leiutis Pharmaceutials LLP · Expires 2036-06-29 · 10y remaining

Vulnerability score 33/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects stable, liquid parenteral formulations of Melphalan or its pharmaceutically acceptable salts.

USPTO Abstract

The present invention relates to stable, liquid parenteral formulations of Melphalan or pharmaceutically acceptable salts thereof. Further this invention also describes process of preparing such formulations.

Drugs covered by this patent

melphalan-hydrochloride (MELPHALAN HYDROCHLORIDE)

Patent Metadata

Patent number: US10537520
Jurisdiction: US
Classification: Formulation
Expires: 2036-06-29
Drug substance claim: No
Drug product claim: Yes
Assignee: Leiutis Pharmaceutials LLP
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.